Balchem (BCPC) to Release Quarterly Earnings on Friday

Balchem (NASDAQ:BCPC) is scheduled to issue its quarterly earnings data before the market opens on Friday, October 25th. Analysts expect the company to announce earnings of $1.03 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Balchem (NASDAQ:BCPC) last released its earnings results on Friday, July 26th. The basic materials company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. Balchem had a return on equity of 10.94% and a net margin of 12.52%. The business had revenue of $234.08 million for the quarter, compared to the consensus estimate of $241.26 million. On average, analysts expect Balchem to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Balchem Trading Down 0.5 %

Balchem stock opened at $166.76 on Thursday. Balchem has a 52 week low of $110.74 and a 52 week high of $186.03. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.79 and a current ratio of 2.83. The stock has a market capitalization of $5.41 billion, a P/E ratio of 47.11, a PEG ratio of 5.43 and a beta of 0.65. The stock has a 50-day simple moving average of $171.60 and a 200 day simple moving average of $162.09.

Insider Buying and Selling

In related news, SVP Gunsteren Job Leonard Van sold 7,750 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $180.05, for a total transaction of $1,395,387.50. Following the sale, the senior vice president now owns 8,540 shares of the company’s stock, valued at $1,537,627. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.25% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have recently commented on BCPC. HC Wainwright upped their target price on Balchem from $170.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, July 31st. StockNews.com downgraded Balchem from a “buy” rating to a “hold” rating in a research report on Monday, July 29th.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.